{"id":"latanoprost-timolol","safety":{"commonSideEffects":[{"rate":"25-50","effect":"Conjunctival hyperemia"},{"rate":"10-25","effect":"Iris pigmentation increase"},{"rate":"10-25","effect":"Eyelash growth (hypertrichosis)"},{"rate":"10-20","effect":"Eye irritation/discomfort"},{"rate":"5-10","effect":"Headache"},{"rate":"1-5","effect":"Bradycardia"},{"rate":"1-5","effect":"Bronchospasm (in susceptible patients)"}]},"_chembl":{"chemblId":"CHEMBL1051","moleculeType":"Small molecule","molecularWeight":"432.60"},"_fixedAt":"2026-03-30T14:10:07.789648","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Latanoprost is a prostaglandin F2α analog that binds to prostaglandin F receptors on the ciliary muscle, facilitating drainage of fluid from the eye through the unconventional uveoscleral pathway. Timolol is a non-selective beta-blocker that reduces aqueous humor secretion by the ciliary body. Together, these complementary mechanisms provide additive intraocular pressure reduction.","oneSentence":"Latanoprost reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor, while timolol decreases aqueous humor production via beta-adrenergic receptor antagonism.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:33:48.662Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"_fixedFields":["pubmed(163)"],"trialDetails":[{"nctId":"NCT05850936","phase":"NA","title":"Effect of IOP Lowering on Progressive HM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-06-01","conditions":"High Myopia, Intraocular Pressure","enrollment":152},{"nctId":"NCT04412096","phase":"PHASE4","title":"Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2020-11-23","conditions":"Glaucoma, OHT - Ocular Hypertension","enrollment":59},{"nctId":"NCT07074782","phase":"","title":"Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues","status":"NOT_YET_RECRUITING","sponsor":"Association for Innovation and Biomedical Research on Light and Image","startDate":"2026-01","conditions":"Glaucoma","enrollment":1500},{"nctId":"NCT06993597","phase":"","title":"Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy","status":"RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2025-09-01","conditions":"Glaucoma","enrollment":60},{"nctId":"NCT02390284","phase":"PHASE3","title":"Stop Retinal Ganglion Cell Dysfunction Study","status":"TERMINATED","sponsor":"University of Miami","startDate":"2015-09","conditions":"Glaucoma","enrollment":28},{"nctId":"NCT06883123","phase":"PHASE4","title":"Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost","status":"RECRUITING","sponsor":"Prairie Eye Center","startDate":"2025-05-14","conditions":"Open Angle Glaucoma","enrollment":70},{"nctId":"NCT06369077","phase":"PHASE4","title":"How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure?","status":"TERMINATED","sponsor":"CT Glaucoma Associates","startDate":"2024-04-22","conditions":"Glaucoma, Open-Angle, Glaucoma; Drugs","enrollment":36},{"nctId":"NCT00579969","phase":"PHASE2","title":"Comparison of Latanoprost Vs. Timolol","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2003-12","conditions":"Glaucoma","enrollment":30},{"nctId":"NCT04702789","phase":"PHASE4","title":"Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension.","status":"TERMINATED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2021-10-19","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":28},{"nctId":"NCT00572936","phase":"PHASE2","title":"Circadian Rhythms of Aqueous Humor Dynamics in Humans","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2006-03-13","conditions":"Glaucoma","enrollment":30},{"nctId":"NCT01191008","phase":"","title":"Long Term Use Of Xalacom In Patients Glaucoma Or Ocular Hypertension","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2010-10","conditions":"Glaucoma, Ocular Hypertension","enrollment":661},{"nctId":"NCT04828057","phase":"","title":"Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting","status":"COMPLETED","sponsor":"Santen Pharmaceutical (Taiwan) Co., LTD","startDate":"2021-09-01","conditions":"Ocular Surface Disease, Primary Open Angle Glaucoma","enrollment":50},{"nctId":"NCT04296916","phase":"NA","title":"Effect of Lowering IOP in Glaucoma Suspects With HM","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-04-17","conditions":"Glaucoma, Suspect, High Myopia","enrollment":264},{"nctId":"NCT05299593","phase":"PHASE4","title":"24-hour Efficacy and Tolerability of the Tafluprost-timolol Fixed Association Without Preservatives in Glaucomatous or Ocular Hypertensive Patients Already Treated With Latanoprost Preserved With BAK. A Prospective, Open Study of 3 Months Duration.","status":"UNKNOWN","sponsor":"Fondazione G.B. Bietti, IRCCS","startDate":"2020-06-04","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":43},{"nctId":"NCT03284853","phase":"PHASE3","title":"Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2017-09-05","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":436},{"nctId":"NCT00383019","phase":"PHASE3","title":"A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2006-11-14","conditions":"Glaucoma, Ocular Hypertension","enrollment":300},{"nctId":"NCT03648229","phase":"PHASE4","title":"African Glaucoma Laser Trial","status":"WITHDRAWN","sponsor":"West Virginia University","startDate":"2019-09-01","conditions":"Open-angle Glaucoma","enrollment":""},{"nctId":"NCT04891588","phase":"NA","title":"Switching From the Preserved to the Preservative - Free Latanoprost - Timolol FC in Glaucoma Patients With OSD","status":"UNKNOWN","sponsor":"Klinički Bolnički Centar Zagreb","startDate":"2021-03-08","conditions":"Primary Open-angle Glaucoma, Ocular Hypertension","enrollment":50},{"nctId":"NCT00143208","phase":"PHASE4","title":"Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom In Patients With Poag Or Oh.","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2003-05","conditions":"Glaucoma, Ocular Hypertension","enrollment":250},{"nctId":"NCT00159653","phase":"PHASE3","title":"A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2005-07","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":500},{"nctId":"NCT00856622","phase":"PHASE3","title":"A Study Demonstrating The Effect Of Latanoprost In Combination With Timolol, Latanoprost Alone And Timolol Alone On Eye Pressure In Open Angle Glaucoma Or Ocular Hypertension In Patients","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"1997-08","conditions":"Ocular Hypertension, Glaucoma, Open-angle Glaucoma","enrollment":436},{"nctId":"NCT00800267","phase":"PHASE3","title":"A Study of Glaucoma or Ocular Hypertension in Patients Within the United States","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"1997-07","conditions":"Ocular Hypertension, Glaucoma","enrollment":418},{"nctId":"NCT00219596","phase":"PHASE3","title":"Xalacom And Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2005-06","conditions":"Glaucoma, Open Angle, Ocular Hypertension","enrollment":240},{"nctId":"NCT00140049","phase":"PHASE4","title":"A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2005-07","conditions":"Glaucoma, Open Angle, Ocular Hypertension","enrollment":238},{"nctId":"NCT00230763","phase":"PHASE3","title":"Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2005-09","conditions":"Glaucoma, Primary Open Angle (POAG), Ocular Hypertension","enrollment":396},{"nctId":"NCT00277498","phase":"PHASE3","title":"A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2005-12","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":528},{"nctId":"NCT00716859","phase":"PHASE3","title":"A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2008-07","conditions":"Glaucoma","enrollment":139},{"nctId":"NCT00751049","phase":"PHASE3","title":"A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within the United Kingdom","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"1992-12","conditions":"Ocular Hypertension, Open Angle Glaucoma","enrollment":294},{"nctId":"NCT00751062","phase":"PHASE3","title":"A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within Scandinavia","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"1992-11","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":267},{"nctId":"NCT00397241","phase":"PHASE4","title":"24-hour Study of Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combinations","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2006-09","conditions":"Open-angle Glaucoma","enrollment":33},{"nctId":"NCT00757835","phase":"PHASE4","title":"24-hr IOP With Travoprost/Timolol Compared With Latanoprost/Timolol in XFG","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2008-05","conditions":"Glaucoma","enrollment":40},{"nctId":"NCT01281020","phase":"","title":"Adherence With Fixed Versus Unfixed Glaucoma Therapy","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2009-05","conditions":"Primary Open-angle Glaucoma, Ocular Hypertension, Exfoliation Glaucoma","enrollment":132},{"nctId":"NCT03612817","phase":"PHASE4","title":"Preservative-free Tafluprost/Timolol Fixed Combination: Morning vs Evening Dosing","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2017-01","conditions":"Glaucoma, Open-Angle","enrollment":42},{"nctId":"NCT02802137","phase":"PHASE4","title":"24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2015-03","conditions":"Glaucoma, Ocular Surface Disease","enrollment":43},{"nctId":"NCT04178863","phase":"PHASE4","title":"CATS Tonometer IOP Reduction Latanoprost Verses Timolol","status":"UNKNOWN","sponsor":"Intuor Technologies, Inc.","startDate":"2018-07-01","conditions":"Glaucoma; Drugs","enrollment":72},{"nctId":"NCT04098861","phase":"PHASE4","title":"Efficacy and Safety of Latanoprost/Timolol for Primary Open Angle Glaucoma","status":"UNKNOWN","sponsor":"Universiti Kebangsaan Malaysia Medical Centre","startDate":"2019-01-02","conditions":"Primary Open Angle Glaucoma","enrollment":40},{"nctId":"NCT03966560","phase":"PHASE4","title":"Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma","status":"COMPLETED","sponsor":"Afyon Kocatepe University Hospital","startDate":"2014-01","conditions":"Glaucoma, Open-Angle","enrollment":96},{"nctId":"NCT00735449","phase":"PHASE4","title":"Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects","status":"COMPLETED","sponsor":"Allergan","startDate":"2008-07","conditions":"Glaucoma, Ocular Hypertension","enrollment":204},{"nctId":"NCT01243567","phase":"PHASE4","title":"Safety and Efficacy of Bimatoprost/Timolol Fixed Combination Versus Latanoprost in Patients With Open-Angle Glaucoma Who Have Never Been Treated","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-06-01","conditions":"Glaucoma, Open-Angle","enrollment":81},{"nctId":"NCT01927406","phase":"PHASE4","title":"The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.","status":"WITHDRAWN","sponsor":"Stanford University","startDate":"2014-06","conditions":"Thyroid Eye Disease, Ocular Hypertension, Glaucoma","enrollment":""},{"nctId":"NCT01917383","phase":"PHASE2","title":"A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma","status":"COMPLETED","sponsor":"Inotek Pharmaceuticals Corporation","startDate":"2013-08","conditions":"Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)","enrollment":101},{"nctId":"NCT01677507","phase":"PHASE4","title":"Glaucoma Biomarkers","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2012-08","conditions":"Glaucoma, Healthy","enrollment":135},{"nctId":"NCT01535768","phase":"PHASE4","title":"Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves","status":"UNKNOWN","sponsor":"Credit Valley EyeCare","startDate":"2012-02","conditions":"Glaucoma","enrollment":150},{"nctId":"NCT02278614","phase":"PHASE3","title":"Efficacy and Safety Assessment of T2347 Versus Xalacom® in Ocular Hypertensive or Glaucomatous Patients","status":"COMPLETED","sponsor":"Laboratoires Thea","startDate":"2014-12","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":242},{"nctId":"NCT01155219","phase":"PHASE4","title":"Safety, Efficacy Assessment of Geltim LP® 1 mg/g in Ocular Hypertensive or Glaucomatous Patients.","status":"COMPLETED","sponsor":"Laboratoires Thea","startDate":"2008-07","conditions":"Glaucoma","enrollment":150},{"nctId":"NCT00906594","phase":"PHASE4","title":"Additive Intra-ocular Pressure Reduction Effect of Fixed Combination of Maleate Timolol 0.5%/Dorzolamide 2% on Monotherapy With Latanoprost in Patients With Elevated Intra-ocular Pressure","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2007-09","conditions":"Glaucoma","enrollment":56},{"nctId":"NCT02522039","phase":"NA","title":"Pupillary Response After Glaucoma Medication","status":"COMPLETED","sponsor":"Glostrup University Hospital, Copenhagen","startDate":"2014-05","conditions":"Drug Effect (Glaucoma Drugs)","enrollment":21},{"nctId":"NCT00913029","phase":"PHASE4","title":"Evaluation of the iStent Versus Two Ocular Hypotensive Agents in Patients With Primary Open-angle Glaucoma (POAG)","status":"COMPLETED","sponsor":"Glaukos Corporation","startDate":"2009-05","conditions":"Eye Diseases, Glaucoma, Open-Angle, Glaucoma","enrollment":192},{"nctId":"NCT00887029","phase":"PHASE4","title":"A 12 Week Comparison of DuoTrav and Xalacom in Open-Angle Glaucoma","status":"COMPLETED","sponsor":"Ophthalmic Consultants Centres, Canada","startDate":"2009-01","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":54},{"nctId":"NCT01175902","phase":"NA","title":"Intraocular Pressure and Ocular Perfusion Pressure of Cosopt in Normal Tension Glaucoma","status":"COMPLETED","sponsor":"The Catholic University of Korea","startDate":"2011-03","conditions":"Normal Tension Glaucoma","enrollment":44},{"nctId":"NCT00706927","phase":"NA","title":"Effect of Xalacom® (Latanoprost/Timolol) and Combigan® (Brimonidine/Timolol) Fixed Combination on Intraocular Pressure and Ocular Blood Flow in Patients With Primary Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2006-01","conditions":"Retina, Ocular Physiology","enrollment":16},{"nctId":"NCT02154217","phase":"PHASE3","title":"Comparison of the Effects of Bimatoprost and a Fixed Combination of Latanoprost and Timolol on 24-hour Blood and Ocular Perfusion Pressures","status":"COMPLETED","sponsor":"University of Milan","startDate":"","conditions":"Glaucoma","enrollment":200},{"nctId":"NCT01263444","phase":"PHASE4","title":"Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-03","conditions":"Glaucoma, Ocular Hypertension","enrollment":47},{"nctId":"NCT01448837","phase":"PHASE4","title":"24-Hour Intraocular Pressure Control With Bimatoprost/Timolol Versus Latanoprost as First Choice","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2010-04","conditions":"Glaucoma","enrollment":37},{"nctId":"NCT01779284","phase":"PHASE4","title":"Travoprost/Timolol vs Latanoprost/Timolol Fixed Combination Therapy","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2012-01","conditions":"Glaucoma","enrollment":42},{"nctId":"NCT00330577","phase":"PHASE4","title":"24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2006-04","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":30},{"nctId":"NCT01302249","phase":"PHASE2","title":"AR-12286 in Combination With Latanoprost","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2011-02","conditions":"Glaucoma, Ocular Hypertension","enrollment":66},{"nctId":"NCT01978015","phase":"PHASE4","title":"Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With POAG","status":"COMPLETED","sponsor":"University of Campinas, Brazil","startDate":"2011-10","conditions":"Uveitis, Anterior, Cystoid Macular Edema","enrollment":69},{"nctId":"NCT01887223","phase":"PHASE2","title":"Transconjunctival Needling Revision Versus Medical Treatment","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2010-05","conditions":"Primary Open Angle Glaucoma","enrollment":40},{"nctId":"NCT00872651","phase":"PHASE3","title":"Travoprost 0.004%/Timolol 0.5% Versus Latanoprost 0.005%/Timolol in Chinese Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-01","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":242},{"nctId":"NCT01151904","phase":"PHASE4","title":"Study of Brimonidine and Timolol Ophthalmic Solution With Latanoprost Compared With Latanoprost in Glaucoma Patients","status":"TERMINATED","sponsor":"Allergan","startDate":"2009-11","conditions":"Glaucoma, Angle-Closure","enrollment":17},{"nctId":"NCT00620256","phase":"PHASE2","title":"Adjunctive Study of AL-37807 Ophthalmic Suspension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2007-11","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":129},{"nctId":"NCT01655758","phase":"PHASE4","title":"24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension","status":"COMPLETED","sponsor":"University of Parma","startDate":"2002-01","conditions":"Ocular Hypertension","enrollment":61},{"nctId":"NCT00912054","phase":"PHASE3","title":"DuoTrav APS Versus XALACOM® in Ocular Surface Health","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2010-03","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":240},{"nctId":"NCT00815373","phase":"NA","title":"The Effects of Cosopt® Vs Xalacom® on Ocular Hemodynamics and Intraocular Pressure (IOP) in Primary Open-angle Glaucoma (POAG)","status":"WITHDRAWN","sponsor":"Meir Medical Center","startDate":"2008-12","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":""},{"nctId":"NCT00287521","phase":"PHASE2","title":"A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2005-11","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":87},{"nctId":"NCT00311389","phase":"PHASE3","title":"A 12-Month Study to Evaluate the Efficacy and Safety of Once-Daily Instillation of Combination Glaucoma Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2003-01","conditions":"Glaucoma, Open-angle, Ocular Hypertension","enrollment":408},{"nctId":"NCT00293800","phase":"PHASE3","title":"A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2004-07","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":173},{"nctId":"NCT00293787","phase":"PHASE3","title":"A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2004-06","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":156},{"nctId":"NCT01304264","phase":"","title":"Intraocular Pressure, Blood Pressure, Ocular Perfusion and Blood Flow Fluctuations in Glaucoma Patients","status":"COMPLETED","sponsor":"Lithuanian University of Health Sciences","startDate":"2011-03","conditions":"Open Angle Glaucoma","enrollment":35},{"nctId":"NCT00811564","phase":"PHASE4","title":"An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects","status":"COMPLETED","sponsor":"Allergan","startDate":"2008-12","conditions":"Glaucoma, Ocular Hypertension","enrollment":148},{"nctId":"NCT00972426","phase":"PHASE4","title":"A Study to Evaluate Efficacy and Safety Effects Using Mikelan® LA Ophthalmic Solution (OS) 2% Versus Timoptol® XE Ophthalmic Solution (OS) 0.5% in Ocular Hypertension Patients","status":"COMPLETED","sponsor":"Taiwan Otsuka Pharm. Co., Ltd","startDate":"2009-10","conditions":"Glaucoma","enrollment":32},{"nctId":"NCT00751127","phase":"PHASE3","title":"A 6 Month Study Comparing Latanoprost With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Pfizer","startDate":"1993-01","conditions":"Glaucoma, Open Angle Glaucoma, Ocular Hypertension","enrollment":268},{"nctId":"NCT00804115","phase":"NA","title":"The International Collaborative Exfoliation Syndrome Treatment Study","status":"UNKNOWN","sponsor":"The New York Eye & Ear Infirmary","startDate":"2000-08","conditions":"Exfoliation Syndrome, Glaucoma, Ocular Hypertension","enrollment":277},{"nctId":"NCT00698945","phase":"PHASE4","title":"Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG)","status":"COMPLETED","sponsor":"Bp Consulting, Inc","startDate":"2008-06","conditions":"Ocular Hypertension, Open-Angle Glaucoma","enrollment":40},{"nctId":"NCT00796198","phase":"PHASE4","title":"Effects of Cosopt on IOP and on Ocular Diastolic Perfusion Pressure","status":"UNKNOWN","sponsor":"University of Turin, Italy","startDate":"2008-12","conditions":"Glaucoma","enrollment":50},{"nctId":"NCT00273481","phase":"PHASE4","title":"Cosopt Versus Xalacom","status":"COMPLETED","sponsor":"Pharmaceutical Research Network","startDate":"2005-09","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":33},{"nctId":"NCT00051155","phase":"PHASE3","title":"A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2001-01","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":""},{"nctId":"NCT00440336","phase":"NA","title":"Comparison of Efficacy of Two Groups of Glaucoma Drops (Xalatan vs.Cosopt) in Reducing Eye Pressure Following Laser (SLT)Treatment in the Management of Glaucoma.","status":"UNKNOWN","sponsor":"Advanced Glaucoma Specialists","startDate":"2006-10","conditions":"Open Angle Glaucoma","enrollment":30},{"nctId":"NCT00442312","phase":"PHASE4","title":"Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost Compared With Latanoprost Monotherapy","status":"UNKNOWN","sponsor":"Genovate Biotechnology Co., Ltd.,","startDate":"2006-05","conditions":"Glaucoma","enrollment":43},{"nctId":"NCT00273429","phase":"PHASE4","title":"Cosopt Versus Xalatan","status":"COMPLETED","sponsor":"Pharmaceutical Research Network","startDate":"2005-04","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":31,"reaction":"DIARRHOEA"},{"count":30,"reaction":"DIZZINESS"},{"count":30,"reaction":"FALL"},{"count":29,"reaction":"OFF LABEL USE"},{"count":28,"reaction":"GENERAL PHYSICAL HEALTH DETERIORATION"},{"count":27,"reaction":"NAUSEA"},{"count":26,"reaction":"DYSPNOEA"},{"count":25,"reaction":"ANAEMIA"},{"count":25,"reaction":"FEBRILE NEUTROPENIA"},{"count":24,"reaction":"FATIGUE"}],"_approvalHistory":[],"publicationCount":163,"recentPublications":[{"date":"2026 Jan 8","pmid":"41507838","title":"Latanoprost/timolol fixed-dose combination: two decades of efficacy and safety in glaucoma management.","journal":"BMC ophthalmology"},{"date":"2025","pmid":"40206242","title":"Periorbital skin hypopigmentation associated with the use of topical glaucoma medications.","journal":"Digital journal of ophthalmology : DJO"},{"date":"2025 Jun","pmid":"39910031","title":"Medicare Part D Glaucoma Drug Prescribing Patterns by Ophthalmologists from 2018 to 2022.","journal":"Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics"},{"date":"2024 Dec","pmid":"39156906","title":"Topical insulin to treat a conjunctival defect after glaucoma surgery: A case report.","journal":"American journal of ophthalmology case reports"},{"date":"2024 May","pmid":"38598266","title":"A Comparative Study on Efficacy of Intraocular Pressure Lowering of Two Fixed-Dose Antiglaucoma Drug Combination Brinzolamide-Brimonidine Versus Latanoprost-Timolol in Primary Open-Angle Glaucoma and Ocular Hypertension.","journal":"Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Latanoprost/Timolol","genericName":"Latanoprost/Timolol","companyName":"Universiti Kebangsaan Malaysia Medical Centre","companyId":"universiti-kebangsaan-malaysia-medical-centre","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Latanoprost reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor, while timolol decreases aqueous humor production via beta-adrenergic blockade. Used for Open-angle glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}